PLoS ONE (Jan 2012)

G-cimp status prediction of glioblastoma samples using mRNA expression data.

  • Mehmet Baysan,
  • Serdar Bozdag,
  • Margaret C Cam,
  • Svetlana Kotliarova,
  • Susie Ahn,
  • Jennifer Walling,
  • Jonathan K Killian,
  • Holly Stevenson,
  • Paul Meltzer,
  • Howard A Fine

DOI
https://doi.org/10.1371/journal.pone.0047839
Journal volume & issue
Vol. 7, no. 11
p. e47839

Abstract

Read online

Glioblastoma Multiforme (GBM) is a tumor with high mortality and no known cure. The dramatic molecular and clinical heterogeneity seen in this tumor has led to attempts to define genetically similar subgroups of GBM with the hope of developing tumor specific therapies targeted to the unique biology within each of these subgroups. Recently, a subset of relatively favorable prognosis GBMs has been identified. These glioma CpG island methylator phenotype, or G-CIMP tumors, have distinct genomic copy number aberrations, DNA methylation patterns, and (mRNA) expression profiles compared to other GBMs. While the standard method for identifying G-CIMP tumors is based on genome-wide DNA methylation data, such data is often not available compared to the more widely available gene expression data. In this study, we have developed and evaluated a method to predict the G-CIMP status of GBM samples based solely on gene expression data.